loader

maze therapeutics

LATEST ARTICLES

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Latest News

More News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES